Table of Contents
Advances in Nephrology
Volume 2014, Article ID 510209, 6 pages
http://dx.doi.org/10.1155/2014/510209
Research Article

Preinterventional Cystatin C: A Highly Prognostic Marker for All-Cause Mortality after Coronarography

Department of Cardiology and Angiology, University Hospital of Muenster, 48129 Muenster, Germany

Received 30 June 2014; Accepted 14 September 2014; Published 25 September 2014

Academic Editor: Carlos G. Musso

Copyright © 2014 Florian Lüders et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Coresh, E. Selvin, L. A. Stevens et al., “Prevalence of chronic kidney disease in the United States,” Journal of the American Medical Association, vol. 298, no. 17, pp. 2038–2047, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” The American Journal of Kidney Diseases, vol. 39, supplement 1, no. 2, pp. S1–S266, 2002. View at Google Scholar
  3. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the american heart aAssociation councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention,” Circulation, vol. 108, no. 17, pp. 2154–2169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. N. S. Anavekar, J. J. V. McMurray, E. J. Velazquez et al., “Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1285–1295, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Ninomiya, Y. Kiyohara, Y. Tokuda et al., “Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan arteriosclerosis longitudinal study,” Circulation, vol. 118, no. 25, pp. 2694–2701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. D. Perrone, N. E. Madias, and A. S. Levey, “Serum creatinine as an index of renal function: new insights into old concepts,” Clinical Chemistry, vol. 38, no. 10, pp. 1933–1953, 1992. View at Google Scholar · View at Scopus
  8. O. F. Laterza, C. P. Price, and M. G. Scott, “Cystatin C: an improved estimator of glomerular filtration rate?” Clinical Chemistry, vol. 48, no. 5, pp. 699–707, 2002. View at Google Scholar · View at Scopus
  9. D. J. Newman, H. Thakkar, R. G. Edwards et al., “Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine,” Kidney International, vol. 47, no. 1, pp. 312–318, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. M. G. Shlipak, R. Katz, M. J. Sarnak et al., “Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease,” Annals of Internal Medicine, vol. 145, no. 4, pp. 237–246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Shlipak, M. J. Sarnak, R. Katz et al., “Cystatin C and the risk of death and cardiovascular events among elderly persons,” The New England Journal of Medicine, vol. 352, no. 20, pp. 2049–2060, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Keller, C. M. Messow, E. Lubos et al., “Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study,” European Heart Journal, vol. 30, no. 3, pp. 314–320, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher, “Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate,” Clinical Chemistry, vol. 51, no. 2, pp. 321–327, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Reinecke, M. Fobker, J. Wellmann et al., “A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) trial,” Clinical Research in Cardiology, vol. 96, no. 3, pp. 130–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. S. Levey, T. Greene, J. W. Kusek, and G. J. Beck, “MDRD Study Group: simplified equation to predict glomerular filtration rate from serum creatinine,” Journal of the American Society of Nephrology, vol. 11, Article ID A0828, 2000. View at Google Scholar
  16. S. C. Smith Jr., J. T. Dove, A. K. Jacobs et al., “ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary angioplasty) Endorsed by the society for Cardiac Angiography and Interventions,” Circulation, vol. 103, no. 24, pp. 3019–3041, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Abrahamson, I. Olafsson, A. Palsdottir et al., “Structure and expression of the human cystatin C gene,” Biochemical Journal, vol. 268, no. 2, pp. 287–294, 1990. View at Google Scholar · View at Scopus
  18. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Herget-Rosenthal, T. Feldkamp, L. Volbracht, and A. Kribben, “Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range,” Annals of Clinical Biochemistry, vol. 41, no. 2, pp. 111–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Madero, M. J. Sarnak, and L. A. Stevens, “Serum cystatin C as a marker of glomerular filtration rate,” Current Opinion in Nephrology and Hypertension, vol. 15, no. 6, pp. 610–616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Pricker, P. Wiesli, M. Brändle, B. Schwegler, and C. Schmid, “Impact of thyroid dysfunction on serum cystatin C,” Kidney International, vol. 63, no. 5, pp. 1944–1947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Levey, R. L. Berg, J. J. Gassman, P. M. Hall, and W. G. Walker, “Creatinine filtration, secretion and excretion during progressive renal disease,” Kidney International, vol. 36, no. 27, pp. S73–S80, 1989. View at Google Scholar · View at Scopus
  23. M. G. Shlipak, C. L. W. Fyr, G. M. Chertow et al., “Cystatin C and mortality risk in the elderly: the health, aging, and body composition study,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 254–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. A. Stevens and A. S. Levey, “Chronic kidney disease in the elderly—how to assess risk,” The New England Journal of Medicine, vol. 352, no. 20, pp. 2122–2124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. V. R. Dharnidharka, C. Kwon, and G. Stevens, “Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis,” The American Journal of Kidney Diseases, vol. 40, no. 2, pp. 221–226, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. R. D. Lindeman, J. Tobin, and N. W. Shock, “Longitudinal studies on the rate of decline in renal function with age,” Journal of the American Geriatrics Society, vol. 33, no. 4, pp. 278–285, 1985. View at Google Scholar · View at Scopus
  27. R. A. DeFronzo, “Diabetic nephropathy: etiologic and therapeutic considerations,” Diabetes Reviews, vol. 3, no. 3, pp. 510–564, 1995. View at Google Scholar · View at Scopus
  28. A. Servais, P. Giral, M. Bernard, E. Bruckert, G. Deray, and C. Isnard Bagnis, “Is serum cystatin-C a reliable marker for metabolic syndrome?” The American Journal of Medicine, vol. 121, no. 5, pp. 426–432, 2008. View at Publisher · View at Google Scholar · View at Scopus